Format

Send to

Choose Destination
Br J Dermatol. 2016 Feb;174(2):463. doi: 10.1111/bjd.14279. Epub 2016 Jan 20.

Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors.

Author information

1
Institute of Pharmaceutical Medicine/ECPM, University Basel, Basel, Switzerland. klazien.matter@unibas.ch.
2
SAKK Coordinating Centre, Bern, Switzerland. klazien.matter@unibas.ch.
3
Department Dermatology, University Hospital Zürich, Zürich, Switzerland.
4
SAKK Coordinating Centre, Bern, Switzerland.
5
Institute of Pharmaceutical Medicine/ECPM, University Basel, Basel, Switzerland.
6
Department Oncology, University Hospital Zürich, Zürich, Switzerland.
PMID:
26787297
DOI:
10.1111/bjd.14279
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center